BRPI0111191B8 - moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos - Google Patents

moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos

Info

Publication number
BRPI0111191B8
BRPI0111191B8 BRPI0111191A BRPI0111191B8 BR PI0111191 B8 BRPI0111191 B8 BR PI0111191B8 BR PI0111191 A BRPI0111191 A BR PI0111191A BR PI0111191 B8 BRPI0111191 B8 BR PI0111191B8
Authority
BR
Brazil
Prior art keywords
mutant molecules
soluble ctla4
production
ctla4
molecules
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
R Naemura Joseph
Bajorath Jurgen
S Linsley Peter
J Peach Robert
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0111191A publication Critical patent/BR0111191A/pt
Publication of BRPI0111191B1 publication Critical patent/BRPI0111191B1/pt
Publication of BRPI0111191B8 publication Critical patent/BRPI0111191B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0111191 2000-05-26 2001-05-23 moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos BRPI0111191B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (3)

Publication Number Publication Date
BR0111191A BR0111191A (pt) 2004-07-06
BRPI0111191B1 BRPI0111191B1 (pt) 2019-12-31
BRPI0111191B8 true BRPI0111191B8 (pt) 2021-05-25

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0111191 BRPI0111191B8 (pt) 2000-05-26 2001-05-23 moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos

Country Status (41)

Country Link
EP (3) EP1248802B9 (OSRAM)
JP (1) JP4328525B2 (OSRAM)
KR (2) KR100895134B1 (OSRAM)
CN (2) CN101255192A (OSRAM)
AR (1) AR031699A1 (OSRAM)
AT (1) ATE271066T1 (OSRAM)
AU (2) AU2001263466C1 (OSRAM)
BE (1) BE2011C041I2 (OSRAM)
BR (1) BRPI0111191B8 (OSRAM)
CA (1) CA2409748C (OSRAM)
CY (2) CY2011019I1 (OSRAM)
CZ (1) CZ304451B6 (OSRAM)
DE (2) DE60104282T2 (OSRAM)
DK (1) DK1248802T3 (OSRAM)
EC (1) ECSP024365A (OSRAM)
EE (2) EE05557B1 (OSRAM)
EG (1) EG24459A (OSRAM)
ES (2) ES2571852T3 (OSRAM)
FR (1) FR11C0053I2 (OSRAM)
GE (1) GEP20053658B (OSRAM)
HK (1) HK1048126B (OSRAM)
HU (2) HU228137B1 (OSRAM)
IL (1) IL152315A (OSRAM)
LT (1) LT5133B (OSRAM)
LU (1) LU91902I2 (OSRAM)
LV (1) LV12994B (OSRAM)
MX (1) MXPA02011534A (OSRAM)
MY (1) MY136113A (OSRAM)
NO (2) NO330797B1 (OSRAM)
PE (1) PE20011338A1 (OSRAM)
PL (1) PL206267B1 (OSRAM)
PT (1) PT1248802E (OSRAM)
RU (1) RU2283847C2 (OSRAM)
SI (1) SI1248802T1 (OSRAM)
SK (1) SK288131B6 (OSRAM)
TR (1) TR200402703T4 (OSRAM)
TW (2) TWI314933B (OSRAM)
UA (1) UA87432C2 (OSRAM)
UY (1) UY26723A1 (OSRAM)
WO (1) WO2001092337A2 (OSRAM)
ZA (1) ZA200208944B (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
IL153593A0 (en) * 2000-07-03 2003-07-06 Bristol Myers Squibb Co A pharmaceutical composition containing a soluble ctla4 mutant molecule
CZ305380B6 (cs) 2001-05-23 2015-08-26 Bristol-Myers Squibb Company Léčivo pro inhibici rejekce transplantovaných buněk ostrůvků slinivky břišní
EP1496931A4 (en) * 2002-04-19 2009-07-01 Bristol Myers Squibb Co METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
DK2253644T3 (da) 2005-12-20 2014-01-13 Bristol Myers Squibb Co Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
US8465741B2 (en) 2006-12-20 2013-06-18 Mmrglobal, Inc. Antibodies and methods for making and using them
PT2612868T (pt) * 2007-11-01 2018-10-24 Astellas Pharma Inc Ácidos nucleicos e polipéptidos imunosupressores
HRP20180045T1 (hr) 2008-10-02 2018-03-23 Aptevo Research And Development Llc Proteini antagonisti cd86 koji se vežu na više meta
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011113019A2 (en) * 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
CA2827492A1 (en) 2011-02-23 2012-08-30 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
DK3207938T3 (da) * 2012-05-11 2020-03-16 Medimmune Ltd Ctla-4-varianter
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CA2877986A1 (en) * 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
CN106029896B (zh) 2014-01-13 2020-10-27 美国安进公司 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
EP3152317B1 (en) 2014-06-04 2019-01-02 Amgen Inc. Methods for harvesting mammalian cell cultures
JP6698681B2 (ja) 2014-12-01 2020-05-27 アムジエン・インコーポレーテツド 糖タンパク質のグリカン含量のレベルを操作するためのプロセス
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
PL3283508T3 (pl) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
CN108350416A (zh) 2015-11-09 2018-07-31 百时美施贵宝公司 操纵在cho细胞中产生的多肽的品质属性的方法
US11261233B2 (en) 2016-09-19 2022-03-01 OncoC4, Inc. CD80 and CD86 binding protein compositions and uses thereof
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
SG11201909797QA (en) 2017-04-20 2019-11-28 Egenesis Inc Methods for generating genetically modified animals
CN111801347A (zh) * 2017-10-10 2020-10-20 高山免疫科学股份有限公司 Ctla-4变体免疫调节蛋白和其用途
US12297253B2 (en) 2018-01-03 2025-05-13 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
CN115551530A (zh) 2019-08-27 2022-12-30 通尼克斯制药有限公司 经修饰的tff2多肽
PE20221770A1 (es) 2019-12-06 2022-11-11 Regeneron Pharma Composiciones de proteina anti-vegf y metodos para producir la misma
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
CA3184812A1 (en) 2020-06-18 2021-12-23 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed c-terminal lysine
WO2022027013A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
CN118647416A (zh) 2021-12-16 2024-09-13 百时美施贵宝公司 用于病毒灭活的洗涤剂
AU2023227209A1 (en) 2022-03-02 2024-09-12 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
KR100238712B1 (ko) * 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
JP2003532370A (ja) * 1998-10-07 2003-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 新規なＴｈ２特異的分子およびその使用方法
IL153593A0 (en) * 2000-07-03 2003-07-06 Bristol Myers Squibb Co A pharmaceutical composition containing a soluble ctla4 mutant molecule

Also Published As

Publication number Publication date
TWI319405B (en) 2010-01-11
CZ304451B6 (cs) 2014-05-14
CN1309735C (zh) 2007-04-11
AU2001263466C1 (en) 2006-10-26
EG24459A (en) 2009-07-16
EP1536234B1 (en) 2016-03-16
HUP0302201A2 (hu) 2003-10-28
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
BR0111191A (pt) 2004-07-06
JP2004511213A (ja) 2004-04-15
HK1048126A1 (en) 2003-03-21
EE200200659A (et) 2004-06-15
CN101255192A (zh) 2008-09-03
EP1536234A3 (en) 2009-06-03
AR031699A1 (es) 2003-10-01
HU228137B1 (en) 2012-12-28
HK1071931A1 (en) 2005-08-05
BE2011C041I2 (OSRAM) 2020-08-20
AU6346601A (en) 2001-12-11
AU2001263466B2 (en) 2006-04-27
UY26723A1 (es) 2001-12-28
ECSP024365A (es) 2003-03-31
SK288131B6 (sk) 2013-10-02
EP1536234A2 (en) 2005-06-01
NO20025656D0 (no) 2002-11-25
DE122011100063I1 (de) 2012-06-14
HUP0302201A3 (en) 2010-01-28
FR11C0053I1 (OSRAM) 2012-01-13
CY1117625T1 (el) 2017-04-26
CA2409748C (en) 2008-09-16
EP1248802B9 (en) 2005-05-11
NO2011027I2 (OSRAM) 2011-12-15
WO2001092337A2 (en) 2001-12-06
NO2011027I1 (no) 2012-01-09
WO2001092337A3 (en) 2002-05-10
KR20030009502A (ko) 2003-01-29
KR100889887B1 (ko) 2009-03-24
HUS1300012I1 (hu) 2016-08-29
IL152315A0 (en) 2003-05-29
PL366231A1 (en) 2005-01-24
DK1248802T3 (da) 2004-11-15
LT2002114A (en) 2003-12-29
TWI314933B (en) 2009-09-21
EP3029062A1 (en) 2016-06-08
JP4328525B2 (ja) 2009-09-09
EE201100050A (et) 2011-10-17
NO20025656L (no) 2002-11-25
ES2571852T3 (es) 2016-05-27
IL152315A (en) 2010-04-15
DE60104282D1 (de) 2004-08-19
EE05557B1 (et) 2012-08-15
PE20011338A1 (es) 2002-01-13
FR11C0053I2 (fr) 2013-01-11
TR200402703T4 (tr) 2004-11-22
MXPA02011534A (es) 2004-08-12
CY2011019I1 (el) 2016-12-14
BRPI0111191B1 (pt) 2019-12-31
HK1048126B (en) 2005-03-04
KR100895134B1 (ko) 2009-05-04
LV12994B (en) 2003-08-20
ES2225549T3 (es) 2005-03-16
CA2409748A1 (en) 2001-12-06
PL206267B1 (pl) 2010-07-30
GEP20053658B (en) 2005-11-10
TW200906857A (en) 2009-02-16
SK15702002A3 (sk) 2004-01-08
PT1248802E (pt) 2004-11-30
ZA200208944B (en) 2004-02-13
CZ20023892A3 (cs) 2003-09-17
EP1248802B1 (en) 2004-07-14
DE60104282T2 (de) 2005-10-13
UA87432C2 (uk) 2009-07-27
LT5133B (lt) 2004-05-25
MY136113A (en) 2008-08-29
ATE271066T1 (de) 2004-07-15
NO330797B1 (no) 2011-07-18
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
RU2283847C2 (ru) 2006-09-20
EE05458B1 (et) 2011-08-15
SI1248802T1 (en) 2005-02-28
CN1441810A (zh) 2003-09-10

Similar Documents

Publication Publication Date Title
BRPI0111191B8 (pt) moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
Mekalanos et al. Enzymic activity of cholera toxin. II. Relationships to proteolytic processing, disulfide bond reduction, and subunit composition.
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
AR036272A1 (es) Genes de metiltransferasas y usos de los mismos
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
BR112022026575A2 (pt) Anticorpos de alta afinidade que alvejam tau fosforilado em serina 413
Bierlmeier et al. Sortase‐Mediated Multi‐Fragment Assemblies by Ligation Site Switching
BR9909639A (pt) Processos para reduzir a alergenicidade de uma proteìna não humana e para produzir uma proteìna tendo reduzida alergenicidade, proteìna mutante tendo reduzida alergenicidade, dna, vetor de expressão, células hospedeiras, composição farmacêutica, e, substilisina humana
BR0315178A (pt) Eritropoietina: remodelagem e glicoconjugação de eritropoietina
BR0015287A (pt) Moléculas recombinantes de fusão
AU2003287115A1 (en) Fluorescent proteins from copepoda species and methods for using same
Humphries et al. Expression of the class 1 outer-membrane protein of Neisseria meningitidis in Escherichia coli and purification using a self-cleavable affinity tag
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
MXPA04005992A (es) Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa.
Albers et al. The sialyl-O-acetylesterase NanS of Tannerella forsythia encompasses two catalytic modules with different regiospecificity for O7 and O9 of sialic acid
Bian et al. The roles of surface loop insertions and disulfide bond in the stabilization of thermophilic WF146 protease
WO2002102852A3 (en) Modified cd8 molecule, nucleic acid encoding said molecule, and their therapeut ic use
FR2792651B1 (fr) Sequence genomique et polypeptides de pyrococcus abyssi, leurs fragments et leurs utilisations
Morgan et al. Structural and functional characterisation of two proteolytic fragments of the bacterial protein toxin, pneumolysin
Kleinschmidt et al. Accelerated Publications Folding Intermediates of a β-Barrel Membrane Protein. Kinetic Evidence for a Multi-Step Membrane Insertion Mechanism
Iseki et al. Purification and liposomal reconstitution of the oligopeptide transport activity in rat renal cortex using ceftibuten-affinity chromatography
Váchová et al. Calcium as a regulator of Bacillus megaterium cytoplasmic proteolytic activity in vitro
WO2005040208A3 (en) Peptides derived from heat shock proteins binding toll-like receptors 2 and 4 and their use
TR200401035T2 (tr) Arıtılmış proteinler, rekombinan DNA dizileri ve kahve bitkilerinin olgunlaşmasını kontrol etmek için işlemler

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/12/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/05/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2724 DE 21/03/2023 POR TER SIDO INDEVIDA.